J0601 Sevelamer Carbonate HCPCS Reimbursement

HCPCS Level II code J0601 denotes sevelamer carbonate, oral, 20 mg, a phosphate binder indicated for patients with end-stage renal disease receiving dialysis. This classification identifies the specific drug formulation used to control serum phosphorus in dialysis populations and is relevant for pharmacy billing, dialysis clinic formularies, and payer coverage determinations. Nationally, accurate coding of oral phosphate binders affects medication access, chronic kidney disease management, and outpatient dialysis cost reporting.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for J0601, its typical sites of service (outpatient pharmacy and dialysis clinics), and the role the code plays in billing workflows. The publication also outlines what stakeholders can expect regarding benchmarks and policy-relevant considerations where available.

This summary presents the clinical and billing identity of J0601, highlights payer relevance for national coverage conversations, and previews the operational details stakeholders will encounter, such as common claim line uses and implications for dialysis patient medication management. Data not available in the input are noted where applicable in detailed sections.

Billing Code Overview

HCPCS Level II code J0601 represents sevelamer carbonate (Renvela or therapeutically equivalent), oral, 20 mg intended for patients with end-stage renal disease (ESRD) on dialysis. The service is a prescription oral medication used to manage hyperphosphatemia in patients with chronic kidney disease who are receiving dialysis.

Service Type: Oral prescription medication (pharmacologic therapy)

Typical Site of Service: Outpatient pharmacy or outpatient dialysis clinic

Clinical Context

A typical patient is a 58-year-old with end-stage renal disease (ESRD) on maintenance hemodialysis who presents to the dialysis center with chronically elevated serum phosphorus despite dietary counseling. The nephrology team prescribes oral J0601 (sevelamer carbonate) to bind intestinal phosphate and lower serum phosphorus. The clinical workflow includes medication reconciliation at the dialysis unit or outpatient clinic, documentation of indication (hyperphosphatemia secondary to ESRD), administration instructions (oral tablets with meals), monitoring of serum phosphate and bicarbonate, and periodic reassessment of tolerability (gastrointestinal side effects) and efficacy. Pharmacy dispensation is documented in the medical record; claims for outpatient oral ESRD-related medications use the HCPCS Level II code J0601 when billing payors that require HCPCS for oral ESRD drugs. Typical site of service is an outpatient dialysis center or outpatient clinic associated with the nephrology practice. The typical patient scenario includes repeated monthly dialysis treatments, coordination between nephrologist, dialysis nursing, and pharmacy, and documentation of concurrent ESRD-related diagnoses on the claim.

Coding Specifications

Modifier	Description	When to Use
`00`	No modifier information	Rarely used; default when no other modifier applies

Taxonomy Code	Specialty	Notes
`208000000X`	Nephrology	Primary specialty managing ESRD and phosphate control; prescribes `J0601`
`174400000X`	Dialysis Facility	Facility-level taxonomy for outpatient dialysis centers where medication management and administration occur
`163W00000X`	Pharmacy	Clinical and dispensing pharmacists handling sevelamer dispensing and medication reconciliation
`363L00000X`	Nurse Practitioner	Advanced practice providers in nephrology clinics or dialysis units who manage prescriptions and follow-up
`207Q00000X`	Internal Medicine	Hospital-based or clinic generalists who may co-manage ESRD patients and renal-related medication therapy

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`N18.6`	End stage renal disease	Primary indication for chronic dialysis and the clinical context in which `J0601` (sevelamer carbonate) is prescribed to manage hyperphosphatemia
`E83.49`	Other disorders of phosphorus metabolism	Captures hyperphosphatemia or phosphate metabolism disorders that may prompt phosphate binder therapy
`N18.9`	Chronic kidney disease, unspecified	Used when CKD stage documentation is incomplete but CKD underlies hyperphosphatemia management
`N18.5`	Chronic kidney disease, stage 5	Advanced CKD often progressing to ESRD; sevelamer may be used prior to or during dialysis initiation
`E83.5`	Disorders of phosphorus metabolism and phosphatases	Code grouping sometimes used for specific phosphate balance disorders treated with phosphate binders

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`80051`	Battery of routine chemistry tests (calcium, phosphorus, etc.)	Serum phosphate and calcium ordering to monitor response to `J0601` therapy; routine lab monitoring before or after dialysis visits
`82570`	Assay of phosphorus (inorganic)	Direct laboratory measurement used to assess hyperphosphatemia and guide sevelamer dosing
`99213`	Office or other outpatient visit for established patient, level 3	Typical outpatient nephrology follow-up visit to prescribe, adjust, or review response to `J0601`
`90935`	Hemodialysis procedure with single evaluation	Dialysis session where medication reconciliation and administration instructions are reinforced; documentation ties ESRD care to drug therapy
`99600`	Handling and/or storage of hazardous or non-hazardous drugs (facility fee)	Facility-level code sometimes used by dialysis centers or pharmacies for handling outpatient medications; applies depending on facility billing practices

OpenPayer

Summary & Overview

HCPCS Level II J0601: Sevelamer Carbonate Oral 20 mg for ESRD on Dialysis